Orion Corporation Financial Statement Release 2017 is now published. Related materials and recorded webcast are also now available on these pages.
|2/7/2018||Notice to the annual general meeting of Orion Corporation|
|2/7/2018||Orion Group Financial Statement Release for 2017|
|1/24/2018||Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2018 AGM of Orion Corporation|
|1/23/2018||Orion to investigate possible sale of Orion Diagnostica|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.